Targeting transcription factor stat5a/b as a therapeutic strategy for prostate cancer

American Journal of Translational Research

Volumn 3, Issue 2, 2011, Pages 133-138

  Liao, Zhiyong ^a   Nevalainen, Marja T ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Prolactin receptor Jak2 Stat5a b signaling pathway; Prostate cancer; Therapy development

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 1480; JANUS KINASE 2; N' [(4 OXO 4H CHROMEN 3 YL)METHYLENE]NICOTINOHYDRAZIDE; PROLACTIN RECEPTOR; STAT5A PROTEIN; STAT5B PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; DIMERIZATION; HUMAN; NONHUMAN; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

MUS MUSCULUS;

EID: 79952967327     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Wakao H, Schmitt-Ney M and Groner B. Mammary gland-specific nuclear factor is present in lactating rodent and bovine mammary tissue and composed of a single polypeptide of 89 kDa. J Biol Chem 1992; 267: 16365-16370.
2. Lin JX, Mietz J, Modi WS, John S and Leonard WJ. Cloning of human Stat5B. Reconstitution of interleukin-2-induced Stat5A and Stat5B DNA binding activity in COS-7 cells. J Biol Chem 1996; 271: 10738-10744.
3. Liu X, Robinson GW, Gouilleux F, Groner B and Hennighausen L. Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci U S A 1995; 92: 8831-8835.
4. Ram PA, Park SH, Choi HK and Waxman DJ. Growth hormone activation of Stat 1, Stat 3, and Stat 5 in rat liver. Differential kinetics of hormone desensitization and growth hormone stimulation of both tyrosine phosphorylation and serine/threonine phosphorylation. J Biol Chem 1996; 271: 5929-5940.
5. Schindler C and Darnell JE, Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 1995; 64: 621-651.
6. Hennighausen L and Robinson GW. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev 2008; 22: 711-721.
7. Gouilleux F, Wakao H, Mundt M and Groner B. Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. Embo J 1994; 13: 4361-4369.
8. Lewis RS and Ward AC. Stat5 as a diagnostic marker for leukemia. Expert Rev Mol Diagn 2008; 8: 73-82.
9. Nikitakis NG, Siavash H and Sauk JJ. Targeting the STAT pathway in head and neck cancer: recent advances and future prospects. Curr Cancer Drug Targets 2004; 4: 637-651.
10. Yu H and Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer 2004; 4: 97-105.
11. Tan SH and Nevalainen MT. Signal transducer and activator of transcription 5A/B in prostate and breast cancers. Endocr Relat Cancer 2008; 15: 367-390.
12. Rouet V, Bogorad RL, Kayser C, Kessal K, Genestie C, Bardier A, Grattan DR, Kelder B, Kopchick JJ, Kelly PA and Goffin V. Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. Proc Natl Acad Sci U S A 2010; 107: 15199-15204.
13. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM and Harkonen PL. Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest 1997; 99: 618-627.
14. Becker S, Groner B and Muller CW. Threedimensional structure of the Stat3beta homodimer bound to DNA. Nature 1998; 394: 145-151.
15. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE, Jr. and Kuriyan J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 1998; 93: 827-839.
16. Reich NC and Liu L. Tracking STAT nuclear traffic. Nat Rev Immunol 2006; 6: 602-612.
17. Kawashima T, Bao YC, Minoshima Y, Nomura Y, Hatori T, Hori T, Fukagawa T, Fukada T, Takahashi N, Nosaka T, Inoue M, Sato T, Kukimoto-Niino M, Shirouzu M, Yokoyama S and Kitamura T. A Rac GTPase-activating protein, MgcRacGAP, is a nuclear localizing signal-containing nuclear chaperone in the activation of STAT transcription factors. Mol Cell Biol 2009; 29: 1796-1813.
18. Vinkemeier U. Getting the message across, STAT! Design principles of a molecular signaling circuit. J Cell Biol 2004; 167: 197-201.
19. Gouilleux F, Pallard C, Dusanter-Fourt I, Wakao H, Haldosen LA, Norstedt G, Levy D and Groner B. Prolactin, growth hormone, erythropoietin and granulocyte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity. Embo J 1995; 14: 2005-2013.
20. Horvath CM, Wen Z and Darnell JE, Jr. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev 1995; 9: 984-994.
21. Soldaini E, John S, Moro S, Bollenbacher J, Schindler U and Leonard WJ. DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites. Mol Cell Biol 2000; 20: 389-401.
22. Boucheron C, Dumon S, Santos SC, Moriggl R, Hennighausen L, Gisselbrecht S and Gouilleux F. A single amino acid in the DNA binding regions of STAT5A and STAT5B confers distinct DNA binding specificities. J Biol Chem 1998; 273: 33936-33941.
23. Yamashita H, Xu J, Erwin RA, Farrar WL, Kirken RA and Rui H. Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells. J Biol Chem 1998; 273: 30218-30224.
24. Decker T and Kovarik P. Serine phosphorylation of STATs. Oncogene 2000; 19: 2628-2637.
25. Yamashita H, Nevalainen MT, Xu J, LeBaron MJ, Wagner KU, Erwin RA, Harmon JM, Hennighausen L, Kirken RA and Rui H. Role of serine phosphorylation of Stat5a in prolactin-stimulated beta-casein gene expression. Mol Cell Endocrinol 2001; 183: 151-163.
26. Nevalainen MT, Harkonen PL, Valve EM, Ping W, Nurmi M and Martikainen PM. Hormone regulation of human prostate in organ culture. Cancer Res 1993; 53: 5199-5207.
27. Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Pretlow TG, Ealley EL, Zhang Y, Nurmi M, Singh B, Martikainen PM and Nevalainen MT. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 2004; 64: 4774-4782.
28. Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, Rui H and Nevalainen MT. Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem 2003; 278: 27287-27292.
29. Dagvadorj A, Collins S, Jomain JB, Abdulghani J, Karras J, Zellweger T, Li H, Nurmi M, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Goffin V and Nevalainen MT. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology 2007; 148: 3089-3101.
30. Dagvadorj A, Kirken RA, Leiby B, Karras J and Nevalainen MT. Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo. Clin Cancer Res 2008; 14: 1317-1324.
31. Gu L, Vogiatzi P, Puhr M, Dagvadorj A, Lutz J, Ryder A, Addya S, Fortina P, Cooper C, Leiby B, Dasgupta A, Hyslop T, Bubendorf L, Alanen K, Mirtti T and Nevalainen MT. Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo. Endocr Relat Cancer 2010; 17: 481-493.
32. Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Addya S, Fortina P, Dasgupta A, Hyslop T, Bubendorf L and Nevalainen MT. Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth. Am J Pathol 2010; 176: 1959-1972.
33. Li H, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, Gelmann EP and Nevalainen MT. Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res 2005; 11: 5863-5868.
34. Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, Zhang Y, Gelmann EP, Zellweger T, Culig Z, Visakorpi T, Bubendorf L, Kirken RA, Karras J and Nevalainen MT. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res 2008; 68: 236-248.
35. Xu X, Kreye E, Kuo CB and Walker AM. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when du145 human prostate cancer cells were grown in nude mice. Cancer Res 2001; 61: 6098-6104.
36. Llovera M, Pichard C, Bernichtein S, Jeay S, Touraine P, Kelly PA and Goffin V. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene 2000; 19: 4695-4705.
37. Verstovsek S. Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program 2009; 636-642.
38. Atallah E and Verstovsek S. Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. Expert Rev Anticancer Ther 2009; 9: 663-670.
39. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008; 22: 23-30.
40. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, Armstrong B, Bebernitz G, Weng S, Wang L, Ye M, McEachern K, Chen H, Morosini D, Bell K, Alimzhanov M, Ioannidis S, McCoon P, Cao ZA, Yu H, Jove R and Zinda M. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009; 16: 487-497.
41. Muller J, Sperl B, Reindl W, Kiessling A and Berg T. Discovery of chromone-based inhibitors of the transcription factor STAT5. Chembiochem 2008; 9: 723-727.
42. Bouchard PR, Hutabarat RM and Thompson KM. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 2010; 50: 237-257.
43. Nagel-Wolfrum K, Buerger C, Wittig I, Butz K, Hoppe-Seyler F and Groner B. The interaction of specific peptide aptamers with the DNA binding domain and the dimerization domain of the transcription factor Stat3 inhibits transactivation and induces apoptosis in tumor cells. Mol Cancer Res 2004; 2: 170-182.